Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
about
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryNonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversalTrends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulantsInterrupting anticoagulation in patients with nonvalvular atrial fibrillation.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsThe effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulantsClinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillationVenous thromboembolism due to suspected interaction between rivaroxaban and nevirapine.Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants.Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old AgentsNovel anticoagulants and laboratory testing.The role of the laboratory in treatment with new oral anticoagulants.Interpretation of coagulation test results under direct oral anticoagulants.Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?Management of hemorrhage with the target-specific oral anticoagulants.Monitoring and reversal strategies for new oral anticoagulants.Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.Drug-drug interactions of non-vitamin K oral anticoagulants.Use of rivaroxaban in patients with stroke.Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention.Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin.Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers.Optical sensing of anticoagulation status: Towards point-of-care coagulation testing.Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.Main considerable factors for correct laboratory test interpretation under DOA treatment.Normal prothrombin time in the presence of therapeutic levels of rivaroxaban.Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia.Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants.Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
P2860
Q26746917-7050429C-459E-4A1D-8DEF-548D86C3BE32Q26828439-80FB765D-EBB8-4DE8-8AE8-039B00C587C5Q28071657-D26CFED1-D7C5-490C-87ED-2879DCBFB622Q33552982-02BF566B-DE08-4DD7-AF85-07CD0E4FF96DQ34688742-A215A203-0AB2-477D-B0BC-1D9FB9B28202Q35154142-48568142-5953-4C8D-95B4-C3C924694297Q35674404-ECEDFBDC-465F-4C9A-A719-3C63CFE2A6C8Q36220098-895EA4F0-33F7-4682-9524-36619C013E02Q36331126-942C2084-D777-4292-8BBB-086E5330E1C1Q36396649-4F119D87-CC3E-482F-A94C-15ACB954B20DQ36594607-DB0FA5A9-2BB6-4621-9F78-5C621B882ABEQ36787628-27E1945C-7690-422A-B3D2-92587DFE1EC6Q36874702-36DD6968-3387-442E-9193-C1DE6FBA2A62Q37495788-BC81B849-7856-4E81-A074-E0CB7CCAD9FAQ38099419-8301BAD7-10E4-481E-A32C-C2F0C5466648Q38117730-AFFDBA1F-F0A8-4634-B2A6-D23AA509B569Q38205947-180E56A1-5B9C-4904-BE75-3B0824A835A9Q38252945-51C5D45D-26CB-4F92-B548-FC1375BE4417Q38254250-5727F1E4-A815-4433-8EB1-DA060F5A31C9Q38272325-73C19025-35ED-4A44-AEFF-85C2DE435016Q38287849-423D5756-4457-4EBC-9F55-4D88FA2F6228Q38365022-A004E53B-EE2F-41EE-B78C-C821A1499B63Q38608242-04D93068-E2E3-42AF-9ADF-52AD52CAC752Q38616901-3CAF6ED2-8E1D-4D71-A7F4-74C8EED08C1AQ38631033-4E967DB7-1C0F-4162-B1D0-B8016CD9F416Q38830358-4250E443-008F-43C2-A278-9D375C1C0DD8Q38941684-B3ED2BC5-7F6A-4BA6-A836-BC3C2380B394Q38956699-8CF47E7D-5A9C-4A0A-9DBB-C017B43A2B40Q39027027-789182CC-5549-499B-9497-0FC7DDB9B70FQ39109136-3D329EF7-4CCC-4B1E-94AF-8194CB167039Q39501760-55FD2B9A-6056-4CCC-A6B1-CEE00C4CD556Q41238308-F4A8F15F-3AB3-4E05-9C93-05CD9B7E1FB8Q41947739-D2F87685-CF4D-4E1B-95E7-2AD5EA0DD8EEQ42862770-AF00304C-80F9-4517-BAA2-0B8AB80DB421Q44834107-9E4A5C11-6BD0-4D39-A732-E91A0A9C4025Q45857724-0B4837FF-ADF5-4329-B8AD-1878A5810839Q46175382-A3E46933-7342-43EE-801A-4963C7BA3A3AQ46702658-AB84610A-CCFA-4AFF-91D3-E4CB956A69AAQ47155567-7BAC8C4D-5795-4F0F-B774-10E7DCBBB984Q48104245-66149463-5D06-4668-BA79-C3905F397126
P2860
Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Assessment of the impact of ri ...... and review of the literature.
@en
type
label
Assessment of the impact of ri ...... and review of the literature.
@en
prefLabel
Assessment of the impact of ri ...... and review of the literature.
@en
P2093
P1433
P1476
Assessment of the impact of ri ...... n and review of the literature
@en
P2093
Bernard Chatelain
Christian Chatelain
Claire Loosen
Jean-Michel Dogné
P304
P356
10.1016/J.THROMRES.2012.09.004
P577
2012-09-21T00:00:00Z